1620107-39-2Relevant academic research and scientific papers
DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
-
Paragraph 00212; 00213; 00214; 00223, (2014/10/04)
Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
De Bruin, Gerjan,Huber, Eva M.,Xin, Bo-Tao,Van Rooden, Eva J.,Al-Ayed, Karol,Kim, Kyung-Bo,Kisselev, Alexei F.,Driessen, Christoph,Van Der Stelt, Mario,Van Der Marel, Gijsbert A.,Groll, Michael,Overkleeft, Herman S.
, p. 6197 - 6209 (2014/08/18)
Mammalian genomes encode seven catalytic proteasome subunits, namely, β1c, β2c, β5c (assembled into constitutive 20S proteasome core particles), β1i, β2i, β5i (incorporated into immunoproteasomes), and the thymoproteasome-specific subunit β5t. Extensive r
